Long-acting coagulation factors and methods of producing same

A method of extending the biological half life of a coagulation factor, comprising the step of attaching one to three chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, wherein said coagulation factor comprising one to three CTPs comprises coagulating activity, wherein said coagulation factor is Factor IX, and wherein said coagulation factor is a wild type coagulation factor, thereby improving the biological half life of said coagulation factor.

A method of improving the area under the curve (AUC) of a coagulation factor, comprising the step of attaching one to three chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, wherein said coagulation factor comprising one to three CTPs comprises coagulating activity, wherein said coagulation factor is Factor IX, and wherein said coagulation factor is a wild type coagulation factor, thereby improving the AUC of said coagulation factor.

A method of reducing the dosing frequency of a coagulation factor, comprising the step of attaching one to three chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, wherein said coagulation factor comprising one to three CTPs comprises coagulating activity, wherein said coagulation factor is Factor IX, and wherein said coagulation factor is a wild type coagulation factor, thereby reducing the dosing frequency of said coagulation factor.

A polypeptide consisting of a wild type coagulation factor and one to five chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein said polypeptide comprises coagulating activity and wherein said coagulation factor is Factor VII or Factor VIIa.

A method of extending the biological half life of a coagulation factor, comprising the step of attaching one to five chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, wherein said coagulation factor comprising one to five CTPs comprises coagulating activity, wherein said coagulation factor is Factor VII or Factor VIIa, and wherein said coagulation factor is a wild type coagulation factor, thereby improving the biological half life of said coagulation factor.

A method of improving the area under the curve (AUC) of a coagulation factor, comprising the step of attaching one to five chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, wherein said coagulation factor comprising one to five CTPs comprises coagulating activity, wherein said coagulation factor is Factor VII or Factor VIIa, and wherein said coagulation factor is a wild type coagulation factor, thereby improving the AUC of said coagulation factor.

A method of reducing the dosing frequency of a coagulation factor, comprising the step of attaching one to five chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, wherein said coagulation factor comprising one to five CTPs comprises coagulating activity, wherein said coagulation factor is Factor VII or Factor VIIa, and wherein said coagulation factor is a wild type coagulation factor, thereby reducing the dosing frequency of said coagulation factor.